Abstract: Compounds of the following general formula (I) and pharmaceutically acceptable salts thereof.

Abstract: A clear gel-type cosmetic product has a viscosity of at least about 50,000 cps at 21.degree. C., and includes an emulsion with an oil phase and a water phase that includes an incorporated active ingredient. The refractive indices of the water and oil phases match to at least 0.0004, the refractive index of the product is about 1.4000, and the product clarity is better than thirty NTU.

Abstract: The present invention relates to a composition, and method of use, of an octahydrobenzo?f!quinoline-based compound represented by structural formula (I). In this formula, R.sup.1 is --OH or --OCH.sub.3 and R.sup.2 is --H, --OH or --OCH.sub.3. In addition, R.sup.3 is a C1 to C2 saturated or unsaturated, alkyl group. Furthermore, R.sup.4 is an aryl group, wherein examples of suitable aryl groups, as defined herein, include phenyl and thienyl groups. The method of this invention relates to the use of the claimed compositions to treat psychotic disorders, to treat Parkinson's disease, or to sedate a mammal by administering an effective amount of a claimed composition.

Abstract: The invention provides the compounds of formula (I) ##STR1## and pharmaceutically acceptable derivatives thereof, in which: X represents either CH.sub.2 --CH.sub.2 or CH.dbd.CH, andY represents a hydrogen atom or a phenylmethyl group, wherein the phenyl group is optionally substituted by one or more halogen atoms.Compounds of formula (I) inhibit blood platelet aggregation.

Abstract: A process for preparing 1-acetyl-4-piperidones of the formula I ##STR1## where R.sup.1, R.sup.2, R.sup.3 and/or R.sup.4 are each a C.sub.1 - to C.sub.6 -alkyl group or R.sup.1 and R.sup.2 together or/and R.sup.3 and R.sup.4 together are an alicyclic hydrocarbon chain having from 2 to 5 carbons, comprises reacting a component comprising the corresponding nonacetylated 4-piperidone with ketene in the presence of a component comprising an acid catalyst at from 20.degree. C. to 120.degree. C.

Abstract: This invention relates to compounds with strong affinity for NK.sub.1 receptor and useful for preparing drugs for treating substance P-dependent pathological conditions having the formula ##STR1## in which: m is two or three;n is 0;Am is a group ##STR2## R.sub.2 is a phenyl which is unsubstituted or monosubstituted or polysubstituted by a halogen atom, a hydroxyl, a (C.sub.1 -C.sub.4)-alkoxy, a (C.sub.1 -C.sub.4)-alkyl or a trifluoromethyl, said substituents being identical or different;X is a hydrogen atom or a hydroxyl group;x is zero or one;Ar is a phenyl which is unsubstituted or monosubstituted or polysubstituted by a halogen atom; a naphthyl; or an indolyl;Z is a phenyl which is disubstituted or polysubstituted by a trifluoromethyl; and the salts thereof with mineral or organic acids and the solvates thereof.

Abstract: A process for preparing a compound of formula (I), wherein n is 2 or 3; which process comprises reducing a compound of formula (II), wherein R.sup.1 is hydrogen or C.sub.1-4 alkyl and n is 2 or 3; by catalytic hydrogenation in the presence of a rhodium catalyst.

Abstract: The invention relates to a compound of the formula I ##STR1## wherein R.sup.1 is a cyclic imide group and X, Y, R.sup.2, and R.sup.3 are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, compounds of the formula I. Compounds of the formula I are useful in the treatment of diseases related to the production of matrix metalloproteinases and tumor necrosis factor.

Abstract: Fibrinogen receptor antagonists having the structureX--Y--Z--A--Band pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g.

Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##

Abstract: Compounds of formula (I): ##STR1## wherein: n,A,R.sup.1,R.sup.2,R.sup.3, and R.sup.4 have meanings as defined herein, or a pharmaceutically acceptable salt thereof, are useful as anti-coagulants.

Abstract: The invention provides certain 5 and/or 8 substituted benzopyran, pyranopyridine or tetrahydroquinaline compounds having C.sub.4 -amide substituent and processes for making them. The compounds described are useful in treating and/or preventing certain disorders.

Abstract: An epoxysuccinic acid derivative having the following formula: ##STR1## ?wherein R.sup.1 is hydrogen, alkyl, aryl, or aralkyl; each of R.sup.2 and R.sup.3 independently is aryl, aralkyl or alkyl; X is --O-- or --NR.sup.4 --; and R.sup.4 is hydrogen, alkyl, or aralkyl! is useful for prevention and treatment of bone diseases such as osteoporosis, malignant hypercalcemia and Paget's syndrome, and further useful for treatment of osteoarthritis and rheumatoid arthritis which are accompanied by abnormal enhancement of cathepsin L activity, and furthermore useful as a medicine for treating diseases in which cathepsin B and L participate, such as muscular dystrophy and muscular atrophy.

Abstract: The present invention relates to compound LK6-A represented by the formula: ##STR1## which has immunosuppressive activity, and pharmaceutically acceptable salts thereof.

Abstract: Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo?3,4-b!quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.

Abstract: Gelled or solid topically-effective compositions comprising a topically-active compound, like an antiperspirant compound; a borate crosslinker; a surfactant, and preferably, a nonionic surfactant or nonionic surfactant blend; a carrier comprising water; and, optionally, a hydrophobic compound, are disclosed.

Abstract: Compounds of the formula ##STR1## are suitable as photoinitiators in free-radical-polymerizable mixtures and are notable for a reduced tendency to diffusion and sublimation than comparable known compounds.

Abstract: Selectin binding and inflammation is modulated by a method which utilizes inositol polyaninon.

Abstract: The present invention relates to optical isomers of quinoline compounds of Formula (IA) or Formula (IA'), their pharmaceutically acceptable salts and their intermediates: ##STR1## In the above formulae, A represent nitrogen or ##STR2## in which Y represents hydrogen, halogen such as fluorine or chlorine, lower alkyl or lower alkoxy such as methoxy, or together with R.sub.1 forms --CH.sub.2 CH.sub.2 CH.sub.2 --, CH.sub.2 CH.sub.2 CH(CH.sub.3)--, --OCH.sub.2 CH.sub.2 --, --OCH.sub.2 CH(CH.sub.3)--, --SCH.sub.2 CH.sub.2 -- or --SCH.sub.2 CH(CH.sub.3)--; R.sub.1 is as defined above or represents straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms, a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms which is substituted with a halogen atom, a phenyl group or a phenyl group substituted with one or two halogen atoms, such as ethyl, cyclopropyl or 2,4-difluorophenyl; R.sub.

Abstract: Novel tocopherol derivatives useful for regulating skin aging and other skin disorders, as well as compositions containing the derivatives and methods for their use are described. The tocopherol derivative is tocopherol-cysteamine. Such types of skin atrophy to be treated the thinning of the epidermis and/or general degradation of the dermis often characterized by hyperplasia and structural disorganization. Such skin maladies include but are not limited to dry skin, severe dry skin, terosis, dandruff, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, blemished skin, hyperpigmented skin, hyperkeratotic skin, inflammatory dermatoses and age-related skin changes.